Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Frederick Kuhn

Cardiovascular Disease Baltimore, MD Medical Doctor

NPI 1245233535 CMS profile 825536

3407 Wilkens Ave, Suite 300, Baltimore, MD 21229

Open in the dashboard

General payments

$5,101

210 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Frederick Kuhn of Baltimore, MD is reported in the CMS Open Payments database as having received $5,101 across 210 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,243 47
2024 General $1,326 40
2023 General $1,015 36
2022 General $474 11
2021 General $310 22
2020 General $62 5
2019 General $672 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Frederick Kuhn
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Frederick Kuhn were reported at $1,243. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Frederick Kuhn Cardiovascular Disease median Middle half National median
2019 $672 $450 $127–$1,392 $163
2020 $62 $242 $77–$751 $114
2021 $310 $335 $101–$1,037 $132
2022 $474 $395 $121–$1,211 $149
2023 $1,015 $443 $136–$1,283 $160
2024 $1,326 $450 $136–$1,323 $164
2025 $1,243 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $858 44 payments
  2. Medtronic, Inc. $646 4 payments
  3. Novartis Pharmaceuticals Corporation $630 41 payments
  4. Abbott Laboratories $463 3 payments
  5. Scpharmaceuticals Inc. $338 10 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $249 11 payments
  7. Esperion Therapeutics, Inc. $209 12 payments
  8. Boston Scientific Corporation $204 4 payments
  9. Baxter Healthcare $195 6 payments
  10. Janssen Pharmaceuticals, Inc $181 9 payments
  11. Other $1,128 66 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,709 208 payments
  2. Consulting Fee $370 1 payment
  3. Education $22 1 payment
Products named General payments · program years 2019–2025
  1. CAMZYOS $515 24 payments
  2. FUROSCIX $338 10 payments
  3. LEQVIO $336 18 payments
  4. ELIQUIS $308 18 payments
  5. ENTRESTO $262 21 payments
  6. NEXLETOL $209 12 payments
  7. AVEIR $185 1 payment
  8. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $177 1 payment
  9. XARELTO $162 8 payments
  10. Hillrom - Cardiac Ambulatory Monitor $153 4 payments
  11. Other $2,063 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 60 drugs

Part D claims

6,046

Median for Cardiology: 2,533

Drug cost

$1,370,174

Median for Cardiology: $485,213

Branded share of claims

24%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 594 $805,649
Entresto Sacubitril/Valsartan Brand 118 $178,585
Xarelto Rivaroxaban Brand 102 $153,862
Repatha Sureclick Evolocumab Brand 72 $86,816
Praluent Pen Alirocumab Brand 30 $23,046
Jardiance Empagliflozin Brand 18 $20,256
Metoprolol Succinate Generic 810 $15,534
Ezetimibe Generic 193 $9,230
Atorvastatin Calcium Generic 489 $8,287
Rosuvastatin Calcium Generic 274 $6,956

The 10 drugs with the highest cost, of 60 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$318,629

Medicare's payments for the services billed

Medicare patients

1,735

Average age 76

Services billed

5,137

938 women, 797 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 47%
Diabetes 36%
Atrial fibrillation 32%
Chronic kidney disease 29%
Heart failure 23%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $126
$126 594 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $109
$109 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $98
$98 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $62
$62 18 —
Wegovy
  • Novo Nordisk Inc $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

210 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record